Brisbane, Calif. — January 5, 2026 — Leads & Copy — Nurix Therapeutics, Inc. (Nasdaq: NRIX) will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 4:30 p.m. PT in San Francisco, the company said today.
Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will be giving the presentation.
The presentation will be available via a live webcast, accessible through a link in the Investors section of the Nurix website. The webcast will be archived and available for 30 days following the event.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing targeted protein degradation medicines. These medicines aim to improve treatment options for patients with cancer and inflammatory diseases.
Nurix’s pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). The company is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline.
Nurix’s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6 in collaboration with Sanofi, a clinical stage degrader of IRAK4 in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc.
Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates within these collaborations.
Nurix is headquartered in Brisbane, California.
Contacts:
Investors
Kris Fortner
Nurix Therapeutics, Inc.
kfortner@nurixtx.com
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Kris Fortner
Nurix Therapeutics, Inc.
Kfortner@nurixtx.com
Source: Nurix Therapeutics, Inc.
